About Us
Return
About Us
Corporate Philosophy
History
Locations
Leadership Team
Quality
Bio-Development Services
Return
Bio-Development Services
Cell Expression Platforms
CHOvolution
®
GEX
®
Fed-Batch & Perfusion
Fast-Track Development
Process Development
CLD
USP
DSP
Analytics
Bio Assay
Formulation Development
Fill & Finish
GMP Manufacturing
Return
GMP Manufacturing
Capabilities & Facilities
Fill & Finish
Cell and Gene Therapy
Return
m
RNA
EVs
Viral Vectors
Cell Therapy
Diagnostics
Insights
Return
Insights
News
Publications
Events
Career
Contact
Insights
News
Filter news by type
Display all news
General
Cell & Gene therapy
Appointments
Growth Investments
Appointments
,
General
Samanta Cimitan Appointed Chief Business Officer at Celonic
May 31, 2022
General
CELONIC TO BECOME A LONG-TERM PARTNER OF THE FEDERAL REPUBLIC OF GERMANY FOR VACCINE SUPPLY
March 24, 2022
General
Celonic’s 2021 Milestones – Looking Beyond the Pandemic
January 19, 2022
General
Celonic’s manufacturing of diagnostics kits is closed
December 20, 2021
General
Conquering Milestones Together with Your CDMO Partner
November 22, 2021
General
Alexandre Pasini appointed Chief Operating Officer at Celonic
October 28, 2021
General
Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV
March 30, 2021
General
Celonic Group and University College London (UCL) Announce Partnership to Produce Protein Therapeutics using Celonic’s CHOvolution
®
Platform
March 22, 2021
General
Live webinar: Difficult-To-Express Protein?
November 18, 2020
General
Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine
July 29, 2020
General
Celonic is proud to support process optimization and GMP manufacturing of a novel COVID19 therapeutic candidate – Airway Therapeutics ‘ AT-100
May 22, 2020
General
Celonic business continuity statement
March 23, 2020
General
Celonic AG Partners with Sparta to Improve Quality and Deliver Higher Customer Satisfaction
December 20, 2018
Next